Watson confirms patent challenge on Welchol
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticals has confirmed that its subsidiary Watson Laboratories has filed an ANDA with the US FDA seeking to market a generic version of Daiichi Sankyo's bile acid sequestrant, Welchol (colesevelam HCl) powder for oral suspension and that it faces a patent infringement charge.